# Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer

> **NCT04862091** · PHASE2 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 69 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** Abiraterone Acetate Tablets (I)
- **DRUG:** ZYTIGA®

## Key facts

- **NCT ID:** NCT04862091
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-23
- **Primary completion:** 2021-10-21
- **Final completion:** 2022-01-06
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2022-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04862091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04862091, "Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04862091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*